TransMedics Group Inc (TMDX) Stock Forecast & Price Target
TransMedics Group Inc · NASDAQ
$88.33-1.65 (-1.83%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering TransMedics Group Inc, 7 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $77.00 to $175.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $118.27 sits 34% above the current $88.33. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.53 next quarter toward $2.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy764%
Hold436%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to TransMedics Group Inc.
As of Sep, 7 of 11 firms rate TMDX a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TMDX EPS & revenue forecast
EPS · NEXT QUARTER
$0.53
Range $0.31 – $0.66 · 8 analysts · +0% YoY
Next period, 8 analysts expect TransMedics Group Inc to earn $0.53 a share (range $0.31 – $0.66), versus $0.53 a year earlier. Full-year consensus is $1.56, growing to $2.31 the year after.
REVENUE · NEXT QUARTER
$201.3M
Range $195.0M – $206.7M · 8 analysts · +25% YoY
Revenue is expected to reach $201.3M (range $195.0M – $206.7M), +25.2% year-over-year. Full-year consensus is $741.7M, rising to $874.7M next year.
Top analysts covering TransMedics Group Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TMDX.
#1
Mike Matson
Needham · Rank #210
Buy
$106.00+20.0% to target
Overall win rate
34%
+ Follow
#2
William Plovanic
Canaccord Genuity · Rank #243
Buy
$95.00+7.6% to target
Overall win rate
37%
+ Follow
#3
Matt O'Brien
Piper Sandler · Rank #424
Buy
$100.00+13.2% to target
Overall win rate
25%
+ Follow
#4
TS
Thomas Stephan
Stifel
Hold
$80.00-9.4% to target
Coverage
—
+ Follow
#5
AG
Allen Gong
JP Morgan
Hold
$73.00-17.4% to target
Coverage
—
+ Follow
TMDX stock forecast FAQ
What is TMDX's average 12-month price target?+
The 11 analysts with a live target average $118.27 for TransMedics Group Inc over the next 12 months, ranging from a $175.00 high to a $77.00 low.
Is TMDX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 7 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TMDX?+
The Street-high target is $175.00 (Oppenheimer), and the Street-low is $77.00 (UBS). The average of all 11 active targets is $118.27.
How many Wall Street analysts cover TMDX?+
11 analysts have an active rating on TransMedics Group Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering TMDX?+
Among analysts who currently cover TMDX, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #210). Their current call is Buy with a $106.00 target.
What is TransMedics Group Inc's projected EPS for next quarter?+
The consensus estimate is $0.53 per share (range $0.31 – $0.66) across 8 analysts. Full-year EPS is projected at $1.56, rising to $2.31 the following year.
How much revenue is TransMedics Group Inc expected to report next quarter?+
Consensus revenue is $201.3M (range $195.0M – $206.7M). Full-year revenue is projected at $741.7M, growing to $874.7M next year.
Have analysts been upgrading or downgrading TMDX lately?+
As of Sep, 7 of 11 firms rate TMDX a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TMDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
